Immunotherapies in cutaneous pathologies: an overview

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study

“…The immune system plays a key role in the pathogenesis of psoriasis, with the involvement of both innate and adaptive immune responses [ 1 , 5 ]. A better understanding of the molecular pathways underlying psoriasis has led to significant advances in the treatment of psoriasis over the past two decades, with the introduction of several biologics [ 5 ].…”

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies*

“…Several immunotherapies have either recently been approved or are currently being developed for the treatment of AD. 35 However, nemolizumab was specifically developed to inhibit the IL‐31 signalling pathway; IL‐31 is known to be a key factor in pruritogenic activity, with additional effects on proinflammatory and immunomodulatory responses. 14 , 15 It is known that an itch–scratch cycle is promulgated in patients with AD and pruritus, resulting in a worsening of rash associated with increased itching.…”

“…Several immunotherapies have either recently been approved or are currently being developed for the treatment of AD. 35 However, nemolizumab was specifically developed to inhibit the IL-31 signalling pathway; IL-31 is known to be a key factor in pruritogenic activity, with additional effects on proinflammatory and immunomodulatory Figure 3 Daily usage of TCS and/or TCI from baseline to the end of the follow-up period (modified intention-to-treat population). The median daily usage was calculated using data collected over a 4-week period.…”

Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment

“…Currently, immunotherapy is used for the treatment of several skin pathologies such as atopic dermatitis (AD), psoriasis (PSO) and cancers, mainly via subcutaneous or intravenous routes. Finding new antibody delivery methods is a challenge and different technologies have emerged in recent years such as microneedle patches, nanoparticles, liposomes or gel formulations [ 1 ]. In addition, several modified antibodies are under development to treat cutaneous diseases, but at present, only certolizumab pegol, a PEGylated anti-tumor necrosis factor α antigen-binding fragment (Fab) has been approved (2013) for the treatment of PSO [ 1 ].…”

“…Finding new antibody delivery methods is a challenge and different technologies have emerged in recent years such as microneedle patches, nanoparticles, liposomes or gel formulations [ 1 ]. In addition, several modified antibodies are under development to treat cutaneous diseases, but at present, only certolizumab pegol, a PEGylated anti-tumor necrosis factor α antigen-binding fragment (Fab) has been approved (2013) for the treatment of PSO [ 1 ]. AD is an inflammatory skin disease with a high and constantly increasing prevalence worldwide (1–3% of adults and 15–20% of children) [ 2 ].…”